Kidney transplant recipients may benefit from new fluid therapy

Cir­cle Phar­ma, a start­up work­ing on macro­cy­cles for the “un­drug­gable,” is seek­ing about $117 mil­lion for a Se­ries D. The com­pa­ny re­cent­ly closed the first

Bone marrow-derived allogeneic stem cell therapy shortly after ischemic stroke did not improve outcomes at 90 days, a phase II/III randomized clinical trial known as